MX2013009732A - Terapias de combinacion comprendiendo agentes anti-erbb3. - Google Patents
Terapias de combinacion comprendiendo agentes anti-erbb3.Info
- Publication number
- MX2013009732A MX2013009732A MX2013009732A MX2013009732A MX2013009732A MX 2013009732 A MX2013009732 A MX 2013009732A MX 2013009732 A MX2013009732 A MX 2013009732A MX 2013009732 A MX2013009732 A MX 2013009732A MX 2013009732 A MX2013009732 A MX 2013009732A
- Authority
- MX
- Mexico
- Prior art keywords
- effective amount
- tumor
- combination therapies
- erbb2
- trastuzumab
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se divulgan métodos y composiciones para inhibir el crecimiento de un tumor (v.gr., un tumor maligno) en un sujeto. En particular, terapias de combinación para tratar un tumor en un sujeto mediante co-administrar ya sea i) una cantidad efectiva de un agente anti-estrógenos o ii) una cantidad efectiva de un inhibidor de receptor tirosina quinasa y una cantidad efectiva de un anticuerpo bi-específico anti-ErbB2/anti-ErbB3, y opcionalmente una cantidad efectiva de trastuzumab. También divulgado es un anticuerpo bi-específico anti-ErbB2/anti-ErbB3 para uso en la terapia o un tumor en combinación con ya sea i) un agente anti-estrógenos o ii) un inhibidor de receptor tirosina quinasa, y opcionalmente en uso con trastuzumab.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161446326P | 2011-02-24 | 2011-02-24 | |
US201161470848P | 2011-04-01 | 2011-04-01 | |
PCT/US2012/026602 WO2012116317A2 (en) | 2011-02-24 | 2012-02-24 | Combination therapies comprising anti-erbb3 agents |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2013009732A true MX2013009732A (es) | 2013-12-06 |
Family
ID=46721477
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013009732A MX2013009732A (es) | 2011-02-24 | 2012-02-24 | Terapias de combinacion comprendiendo agentes anti-erbb3. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20140056898A1 (es) |
EP (1) | EP2678359A4 (es) |
JP (1) | JP2014511383A (es) |
KR (1) | KR20140053865A (es) |
CN (1) | CN103547598A (es) |
AU (1) | AU2012222094A1 (es) |
BR (1) | BR112013021660A2 (es) |
CA (1) | CA2828099A1 (es) |
IL (1) | IL228095A0 (es) |
MX (1) | MX2013009732A (es) |
WO (1) | WO2012116317A2 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2716301T (pt) | 2007-02-16 | 2017-07-04 | Merrimack Pharmaceuticals Inc | Anticorpos contra erbb3 e suas utilizações |
KR101798679B1 (ko) | 2010-03-11 | 2017-11-16 | 메리맥 파마슈티컬즈, 인크. | 3중 음성 및 기저형 유방암 치료 시의 erbb3 저해제의 용도 |
EP2815765A1 (en) * | 2011-03-15 | 2014-12-24 | Merrimack Pharmaceuticals, Inc. | Overcoming resistance to ERBB pathway inhibitors |
CA2873111A1 (en) * | 2012-05-11 | 2013-11-14 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of bispecific scfv conjugates in combination with anti-cancer therapeutics |
WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
AU2015223566B2 (en) | 2014-02-28 | 2020-10-08 | Merus N.V. | Antibodies that bind EGFR and ErbB3 |
US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
PL3365373T3 (pl) | 2015-10-23 | 2021-08-23 | Merus N.V. | Molekuły wiążące, które hamują wzrost nowotworu |
KR102481242B1 (ko) * | 2016-12-01 | 2022-12-23 | 옥스포드 바이오다이나믹스 피엘씨 | 암 진단에서 후생적 염색체 상호 작용의 적용 |
IL269656B1 (en) | 2017-03-31 | 2024-02-01 | Merus Nv | Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene |
AU2018271157C1 (en) * | 2017-05-17 | 2021-11-18 | Merus N.V. | Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancer |
CN111094351A (zh) | 2017-08-09 | 2020-05-01 | 美勒斯公司 | 结合EGFR和cMET的抗体 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8927694B2 (en) * | 2008-11-18 | 2015-01-06 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
US20140017264A1 (en) * | 2010-12-10 | 2014-01-16 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of bispecific scfv conjugates |
-
2012
- 2012-02-24 CN CN201280019977.7A patent/CN103547598A/zh active Pending
- 2012-02-24 CA CA2828099A patent/CA2828099A1/en not_active Abandoned
- 2012-02-24 MX MX2013009732A patent/MX2013009732A/es not_active Application Discontinuation
- 2012-02-24 JP JP2013555616A patent/JP2014511383A/ja active Pending
- 2012-02-24 BR BR112013021660A patent/BR112013021660A2/pt not_active IP Right Cessation
- 2012-02-24 KR KR1020137025188A patent/KR20140053865A/ko not_active Application Discontinuation
- 2012-02-24 WO PCT/US2012/026602 patent/WO2012116317A2/en active Application Filing
- 2012-02-24 EP EP12749889.7A patent/EP2678359A4/en not_active Withdrawn
- 2012-02-24 AU AU2012222094A patent/AU2012222094A1/en not_active Abandoned
- 2012-02-24 US US14/001,448 patent/US20140056898A1/en not_active Abandoned
-
2013
- 2013-08-22 IL IL228095A patent/IL228095A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2012116317A2 (en) | 2012-08-30 |
EP2678359A4 (en) | 2015-01-28 |
US20140056898A1 (en) | 2014-02-27 |
JP2014511383A (ja) | 2014-05-15 |
KR20140053865A (ko) | 2014-05-08 |
WO2012116317A3 (en) | 2013-11-14 |
CN103547598A (zh) | 2014-01-29 |
EP2678359A2 (en) | 2014-01-01 |
IL228095A0 (en) | 2013-09-30 |
AU2012222094A1 (en) | 2013-10-10 |
BR112013021660A2 (pt) | 2018-06-12 |
CA2828099A1 (en) | 2012-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2013009732A (es) | Terapias de combinacion comprendiendo agentes anti-erbb3. | |
PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
MX2018013848A (es) | Combinacion de anticuerpos anti-pd-1s y radiacion para tratar cancer. | |
IN2014KN00871A (es) | ||
EA201300996A1 (ru) | Использование ингибиторов рецепторов семейства egfr в лечении гормонорезистентного рака молочной железы | |
MX357833B (es) | Tratamiento del cancer con inhibidores de tor cinasa. | |
SG194701A1 (en) | Anti-cd40 antibodies and methods of use | |
MX341076B (es) | Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados. | |
MX344355B (es) | Uso de inhibidores de erbb3 en el tratamiento de canceres de mama triple negativos y de tipo basal. | |
WO2010019702A3 (en) | Ddr1-binding agents and methods of use thereof | |
WO2011146568A8 (en) | Predicting response to a her inhibitor | |
MX2014011500A (es) | Diagnosticos y tratamientos relacionados a inhibidores her3. | |
MX2011010955A (es) | Terapia complementaria contra el cancer. | |
PH12014502047B1 (en) | Treatment of cancer with tor kinase inhibitors | |
MX348941B (es) | Medios y metodos para trata y/o prevenir el cancer dependiente del ligando natural de receptor de aril-hidrocarburo. | |
MX360774B (es) | Antagonistas de progesterona. | |
MX2012010212A (es) | Terapias inhibidoras de autofagia basadas en tioxantona para tratar el cancer. | |
PH12015500867A1 (en) | Treatment of prostate cancer with tor kinase inhibitors | |
MX2014004991A (es) | Combinaciones terapeuticas y metodos para tratar el melanoma. | |
MX2013010524A (es) | Combinacion de oligonucleotido anti-clusterina con inhibidor hsp90 para el tratamiento de cancer de prostata. | |
NZ625758A (en) | Method for treating breast cancer | |
MX2022001411A (es) | Metodos para tratar o prevenir canceres que implican la administracion de agentes receptores anti-ccr5. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |